Notice of allowance in European patent application

We are pleased to announce that we have received a notice of allowance (Communication under Rule 71(3) EPC) in our European patent application relating to novel sortilin inhibitors. Sortina’s sortilin inhibitors hold promise in treatment of, among others, cancer and neurodegenerative diseases. This milestone represents a significant advancement in our efforts to protect and further develop innovative therapeutic solutions. The European patent will be instrumental in supporting continued progress across all our projects, with cancer as main focus. We are excited about the opportunities this approval opens up for us in Europe as we move closer to delivering life-saving therapies to patients in need.